BridgeBio Oncology (BBOT) announced the appointment of Pedro Beltran as CEO and Idan Elmelech as COO effective April 20. This transition reflects BridgeBio Oncology entering a new phase of development as the company’s three clinical assets enter expansions and combinations across multiple RAS-driven cancers. Beltran joined BridgeBio Pharma in 2020 as senior VP of biology and became chief scientific officer of BridgeBio Oncology in July 2023.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818
- 3 Best Stocks to Buy Today, According to Top Analysts
- BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility
- BridgeBio Oncology announces publication of preclinical data on BBO-11818
- BridgeBio Oncology price target raised to $29 from $27 at H.C. Wainwright